NMRA stock touches 52-week low at $1.25 amid sharp annual decline

Neumora Therapeutics Inc. (NMRA) stock has reached a 52-week low, trading at $1.25, as investors grapple with the company’s significant downturn over the past year. According to InvestingPro data, while the company maintains a strong current ratio of 10.51 and holds more cash than debt on its balance sheet, it’s quickly burning through available cash. The biotechnology firm, which focuses on precision medicines for brain diseases, has seen its shares plummet, reflecting a staggering 1-year change of -90.96%. This sharp decline has raised concerns among shareholders and market analysts alike, as the company navigates through a challenging period marked by investor skepticism and broader market volatility. Despite the downturn, three analysts have recently revised their earnings expectations upward for the upcoming period. The current price level represents a critical juncture for Neumora Therapeutics, as it strives to regain investor confidence and stabilize its stock performance in the coming months. For deeper insights into NMRA’s financial health and future prospects, including 12 additional exclusive ProTips, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Neumora Therapeutics reported its fourth-quarter 2024 financial results, exceeding earnings expectations with an adjusted loss per share of -$0.37 compared to the anticipated -$0.62. The company also announced a temporary pause in its KOASTAL-2 and KOASTAL-3 studies for navacaprant, aiming to resume in March 2025 after implementing trial optimizations. In response to these developments, Stifel downgraded Neumora from Buy to Hold, reducing the price target to $2.00, citing concerns over the efficacy of the KORA mechanism following Johnson & Johnson’s discontinuation of its similar aticaprant program. William Blair also downgraded Neumora to Market Perform due to the challenges faced by the KOR antagonist approach in major depressive disorder treatment. Conversely, H.C. Wainwright maintained a Buy rating with an $18.00 target, expressing confidence in Neumora’s differentiated pharmacology. Guggenheim reiterated its Buy rating with a $7.00 target, highlighting upcoming data releases and potential advancements in Neumora’s pipeline. Despite leadership changes, Neumora remains focused on optimizing its clinical trials and advancing its research programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.